Company profile
VALNEVA SE
NASDAQ:VALNBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IXCHIQ | approved | — | 0 | — |
| IXIARO | approved | — | 0 | — |
| JAPANESE ENCEPHALITIS VIRUS STRAIN SA 14-14-2 ANTIGEN (FORMALDEHYDE INACTIVATED) | phase4 | — | 11 | completed, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (38)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06028841 | phase3 | withdrawn | 2024-04-10 | 2024-08-27 | Valneva Austria GmbH | A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV) |
| NCT06106581 | phase2 | completed | 2023-12-18 | 2024-07-31 | Valneva Austria GmbH | A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years |
| NCT07133178 | phase3 | withdrawn | 2026-02-06 | 2026-12-01 | Valneva Austria GmbH | A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children |
| NCT01296386 | phase1 | completed | 2010-12-01 | 2013-04-01 | Valneva Austria GmbH | An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84 |
| NCT04838444 | phase3 | active_not_recruiting | 2021-04-02 | 2023-03-03 | Valneva Austria GmbH | Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553) |
FDA applications (2)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 125777 | 2023-11-09 | BLA | VALNEVA AUSTRIA GMBH | |||||
Loading… | ||||||||
| BLA 125280 | 2009-03-30 | BLA | VALNEVA AUSTRIA GMBH | |||||
Loading… | ||||||||